Filgotinib is a selective Janus kinase 1 (JAK1) inhibitor primarily indicated for the treatment of rheumatoid arthritis and other chronic inflammatory conditions. To support the rigorous analytical requirements… Read more
![Chemical structure of 4,4'-([1,1'-Biphenyl]-4,4'-diylbis(methylene))bis(thiomorpholine 1,1-dioxide)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2756973-43-8-44-11-Biphenyl-44-diylbismethylenebisthiomorpholine-11-dioxide.png&w=3840&q=75)
![Chemical structure of 4-(4-(2-Amino-[1,2,4]triazolo[1,5-a]pyridin-5-yl)benzyl)thiomorpholine 1,1-dioxide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1257705-09-1-4-4-2-Amino-124triazolo15-apyridin-5-ylbenzylthiomorpholine-11-dioxide.png&w=3840&q=75)
![Chemical structure of 5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-amine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1010120-55-4-5-Bromo-124triazolo15-apyridin-2-amine.png&w=3840&q=75)



![Chemical structure of N-(5-(4-(Hydroxymethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1142936-49-9-N-5-4-Hydroxymethylphenyl-124triazolo15-apyridin-2-ylcyclopropanecarboxamide.png&w=3840&q=75)
![Chemical structure of N-(5-(p-Tolyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1142936-90-0-N-5-p-Tolyl-124triazolo15-apyridin-2-ylcyclopropanecarboxamide.png&w=3840&q=75)
![Chemical structure of N-(5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1142943-96-1-N-5-Bromo-124triazolo15-apyridin-2-ylcyclopropanecarboxamide.png&w=3840&q=75)
![Chemical structure of N-([1,2,4]Triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1824623-84-8-N-124Triazolo15-apyridin-2-ylcyclopropanecarboxamide.png&w=3840&q=75)
Filgotinib is a selective Janus kinase 1 (JAK1) inhibitor primarily indicated for the treatment of rheumatoid arthritis and other chronic inflammatory conditions. To support the rigorous analytical requirements of pharmaceutical development, this category provides a comprehensive selection of Filgotinib reference standards, including impurities, degradation products, and stable isotope-labelled compounds. Laboratories utilize these high-quality materials for impurity profiling, method validation, and ongoing quality control to ensure the safety and efficacy of the active pharmaceutical ingredient. By offering structurally characterized related compounds, such as synthetic intermediates and stress-degradation products, this collection assists researchers in identifying and quantifying potential contaminants throughout the drug manufacturing lifecycle. These reference standards are essential for maintaining compliance with regulatory guidelines and achieving precise results in stability studies and routine testing protocols.